Larimar Therapeutics, Inc.
LRMR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $73,278 | $27,670 | $24,250 | $38,396 |
| G&A Expenses | $17,612 | $14,088 | $12,276 | $12,069 |
| SG&A Expenses | $17,612 | $14,088 | $12,276 | $12,069 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $90,890 | $41,758 | $36,526 | $50,465 |
| Operating Income | -$90,890 | -$41,758 | -$36,526 | -$50,465 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $10,286 | $4,809 | $1,171 | -$171 |
| Pre-Tax Income | -$80,604 | -$36,949 | -$35,355 | -$50,636 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$80,604 | -$36,949 | -$35,355 | -$50,636 |
| % Margin | – | – | – | – |
| EPS | -1.32 | -0.84 | -1.33 | -2.93 |
| % Growth | -57.1% | 36.8% | 54.6% | – |
| EPS Diluted | -1.32 | -0.84 | -1.33 | -2.93 |
| Weighted Avg Shares Out | 61,256 | 43,901 | 25,761 | 17,164 |
| Weighted Avg Shares Out Dil | 61,256 | 43,901 | 25,761 | 17,164 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $318 | $311 | $318 | $326 |
| EBITDA | -$90,572 | -$41,447 | -$36,208 | -$50,139 |
| % Margin | – | – | – | – |